Avastin Takes One Step Forward, One Step Back At ASCO
This article was originally published in The Pink Sheet Daily
Genentech’s bevacizumab was the subject of one study supporting use in cervical cancer and one failing to show an effect in first-line brain cancer. A separate study repeated the disappointing brain cancer results, but the sponsor sees a silver lining in the quality of life dataset.
You may also be interested in...
U.S. FDA approval is fifth indication for Roche/Genentech’s Avastin. The number of cases in the U.S. is low and set to decline with better prevention, but disease is still considered a major global health problem.
Genentech Aims For Broad Access To Avastin In Cervical Cancer, But Needs To Figure Out How To Get There
FDA approval is fifth indication for Roche/Genentech’s Avastin. Number of cases in the U.S. is low and set to decline with better prevention, but disease is considered a major global health problem.
Genentech’s bevacizumab was associated with improved maintenance of baseline quality of life and performance status in a confirmatory trial conducted under accelerated approval, but an NCI-funded study found higher rates of neurocognitive decline, increased symptom severity and decline in health-related quality of life.